Opinion 1 Nov 2023 Could this be the start of a new era for PI3K drugs? There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […] November 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 5 advancements in rare disease research over the past year There are more than 7,000 rare diseases that affect hundreds of millions of people worldwide. As Rare Disease Day is observed on February 28, here are five recent advancements that have transformed research and boosted the scope for the development of novel therapies. FDA approves tissue-agnostic therapies for rare cancers Tissue-agnostic drug development has been […] February 28, 2023 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 10 biotech companies making a difference in rare diseases February 28 is Rare Disease Day, which looks to raise awareness of rare diseases and bring about change for patients and families living with them. The event also brings attention to the need for improved access to diagnosis, as well as the need to develop more treatments to tackle a broader range of diseases. There […] February 28, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 Cancer: what are the barriers to research? Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day coming up on February 4, we took the opportunity to ask some life science company CEOs, CMOs, and chief scientific officers the same question about cancer research. We asked CellCentric CEO, Will West; iOnctura CEO, Catherine Pickering; ISA Pharmaceuticals chief […] February 1, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 How can cancer care be improved? Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the Care Gap. The question, what are the biggest opportunities to improve cancer care, brought responses from Versameb CEO, Klaas Zuideveld; ImaginAb CEO, Ian Wilson; ISA […] February 1, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 iOnctura raises €17.5M for pancreatic cancer therapy iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2020 Merck Spinout Bags €15M Series A to Tackle Cancer and Fibrosis iOnctura, a spinout from Merck KGaA, has raised €15M to take its cancer and fibrosis drugs to phase I clinical trials. The Series A round was co-led by new investors INKEF Capital and VI Partners. The founding investor of iOnctura, M Ventures — the corporate venture arm of Merck — also contributed to the round, […] January 23, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Dec 2019 Industry Perspectives: Women in Biotech 2019 Women are underrepresented in biotech leadership roles in Europe, but things are slowly improving. We spoke to five senior women from the industry who told us their stories. At least half of life sciences and medical students across Europe are women. In the biotech and pharma industry, this statistic is similar in entry level jobs, […] December 3, 2019 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email